A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial. A systematic review of the published clinical trials of these patients could reduce the possible bias of single phase-II studies. A systematic search i...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 January 2006
|
| In: |
British journal of haematology
Year: 2006, Volume: 132, Issue: 5, Pages: 584-593 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/j.1365-2141.2005.05914.x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1365-2141.2005.05914.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2005.05914.x 
|
| Author Notes: | Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie von Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschlüter |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1789623464 | ||
| 003 | DE-627 | ||
| 005 | 20230426075810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220215s2006 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2141.2005.05914.x |2 doi | |
| 035 | |a (DE-627)1789623464 | ||
| 035 | |a (DE-599)KXP1789623464 | ||
| 035 | |a (OCoLC)1341441742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Glasmacher, Axel |e VerfasserIn |0 (DE-588)1104849275 |0 (DE-627)862193001 |0 (DE-576)472914553 |4 aut | |
| 245 | 1 | 2 | |a A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma |c Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie von Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschlüter |
| 264 | 1 | |c 26 January 2006 | |
| 264 | 4 | |c © 2005 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.02.2022 | ||
| 520 | |a The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial. A systematic review of the published clinical trials of these patients could reduce the possible bias of single phase-II studies. A systematic search identified 42 communications reporting on 1674 patients. Thirty-two trials used an escalating dosing regimen and four a fixed dose regimen (one dose with 50 mg/d, three doses with 200 mg/d). The target dose in the dose escalating trials was 800 mg/d in 17 trials, 400-600 mg/d in 10 and 200 mg/d in one trial. The intention-to-treat population for efficacy was 1629 patients with a median age of 62 years. The complete and partial (>50% reduction in monoclonal protein) response rate was 29·4% (95%-confidence interval, 27-32%). The rates for minor responses or stable disease were 13·8% (12-16%) and 11·0% (9-13%). Progressive disease was reported in 9·9% (8-11%). The median overall survival from all trials was reported at 14 months. Severe adverse events (grade III-IV) included somnolence 11%, constipation 16%, neuropathy 6%, rash 3%, thrombo-embolism 3%, cardiac 2%. In conclusion, thalidomide monotherapy achieved complete and partial responses in 29·4% of patients with relapsed or refractory multiple myeloma. | ||
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a systematic review | |
| 650 | 4 | |a thalidomide | |
| 700 | 1 | |a Hahn, Corinna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Naumann, Ralph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Lilienfeld-Toal, Marie von |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orlopp, Katjana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt-Wolf, Ingo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gorschlüter, Marcus |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 132(2006), 5 vom: Jan., Seite 584-593 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:132 |g year:2006 |g number:5 |g month:01 |g pages:584-593 |g extent:10 |a A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1111/j.1365-2141.2005.05914.x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2005.05914.x |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220215 | ||
| 993 | |a Article | ||
| 994 | |a 2005 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1789623464 |e 4059964441 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 15.02.2022"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2006","dateIssuedDisp":"26 January 2006"}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"name":{"displayForm":["Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie von Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschlüter"]},"id":{"eki":["1789623464"],"doi":["10.1111/j.1365-2141.2005.05914.x"]},"relHost":[{"pubHistory":["1.1955 -"],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"id":{"doi":["10.1111/(ISSN)1365-2141"],"eki":["269758941"],"issn":["1365-2141"],"zdb":["1475751-5"]},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 08.05.08"],"origin":[{"dateIssuedDisp":"1955-","dateIssuedKey":"1955","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"269758941","part":{"issue":"5","year":"2006","pages":"584-593","volume":"132","text":"132(2006), 5 vom: Jan., Seite 584-593","extent":"10"},"disp":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myelomaBritish journal of haematology","title":[{"title_sort":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology","title":"British journal of haematology"}],"language":["eng"],"corporate":[{"display":"British Society for Haematology","roleDisplay":"Herausgebendes Organ","role":"isb"},{"display":"European Hematology Association","roleDisplay":"Herausgebendes Organ","role":"isb"}]}],"language":["eng"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","family":"Glasmacher","given":"Axel","display":"Glasmacher, Axel"},{"family":"Hahn","roleDisplay":"VerfasserIn","role":"aut","display":"Hahn, Corinna","given":"Corinna"},{"roleDisplay":"VerfasserIn","family":"Hoffmann","role":"aut","display":"Hoffmann, Florian","given":"Florian"},{"roleDisplay":"VerfasserIn","family":"Naumann","role":"aut","display":"Naumann, Ralph","given":"Ralph"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Goldschmidt","given":"Hartmut","display":"Goldschmidt, Hartmut"},{"display":"Lilienfeld-Toal, Marie von","given":"Marie von","family":"Lilienfeld-Toal","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Orlopp","roleDisplay":"VerfasserIn","role":"aut","display":"Orlopp, Katjana","given":"Katjana"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Schmidt-Wolf","given":"Ingo","display":"Schmidt-Wolf, Ingo"},{"given":"Marcus","display":"Gorschlüter, Marcus","role":"aut","family":"Gorschlüter","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma"}],"recId":"1789623464"} | ||
| SRT | |a GLASMACHERSYSTEMATIC2620 | ||